The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial.

ABSTRACT:

Background

Membranous nephropathy is a renal autoimmune disease associated with autoantibodies against phospholipase A2 receptor (PLA2R1) in 50-80% of cases. Patients develop immunity towards a single or multiple PLA2R1 domains, defining a cascade immunization or epitope spreading associated with worse prognosis and low rate of spontaneous remission. We aimed to compare the efficacy of standard versus personalized treatment (based on biomarker: epitope spreading) with the immunosuppressor rituximab on remission rate at month-12.

Methods

A randomized, prospective clinical trial (NCT03804359) was conducted in 12 French hospitals. Enrollment between November 2019 and October 2022. Follow-up lasted two years after inclusion and ended in October 2024. Sixty-four patients with PLA

SUBMITTER: Brglez V 

PROVIDER: S-EPMC12664402 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature